These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29054987)

  • 1. Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma.
    Krasniqi A; D'Huyvetter M; Xavier C; Van der Jeught K; Muyldermans S; Van Der Heyden J; Lahoutte T; Tavernier J; Devoogdt N
    Mol Cancer Ther; 2017 Dec; 16(12):2828-2839. PubMed ID: 29054987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20.
    Krasniqi A; Bialkowska M; Xavier C; Van der Jeught K; Muyldermans S; Devoogdt N; D'Huyvetter M
    N Biotechnol; 2018 Oct; 45():69-79. PubMed ID: 29574274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and Preclinical Evaluation of (177)Lu-CHX-A"-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma.
    Kameswaran M; Pandey U; Dhakan C; Pathak K; Gota V; Vimalnath KV; Dash A; Samuel G
    Cancer Biother Radiopharm; 2015 Aug; 30(6):240-6. PubMed ID: 26066665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical study of
    Durand-Panteix S; Monteil J; Sage M; Garot A; Clavel M; Saidi A; Torgue J; Cogne M; Quelven I
    Br J Cancer; 2021 Dec; 125(12):1657-1665. PubMed ID: 34671126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
    Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cure of Micrometastatic B-Cell Lymphoma in a SCID Mouse Model Using
    Havlena GT; Kapadia NS; Huang P; Song H; Engles J; Brechbiel M; Sgouros G; Wahl RL
    J Nucl Med; 2023 Jan; 64(1):109-116. PubMed ID: 35981897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.
    Yadav MP; Singla S; Thakral P; Ballal S; Bal C
    Nucl Med Commun; 2016 Jul; 37(7):735-42. PubMed ID: 26974315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of
    Repetto-Llamazares AHV; Malenge MM; O'Shea A; Eiríksdóttir B; Stokke T; Larsen RH; Dahle J
    Eur J Haematol; 2018 Oct; 101(4):522-531. PubMed ID: 29993152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical efficacy of hK2 targeted [
    Timmermand OV; Elgqvist J; Beattie KA; Örbom A; Larsson E; Eriksson SE; Thorek DLJ; Beattie BJ; Tran TA; Ulmert D; Strand SE
    Theranostics; 2019; 9(8):2129-2142. PubMed ID: 31149033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
    Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
    J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
    Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiolabeled F(ab')
    Bellaye PS; Moreau M; Raguin O; Oudot A; Bernhard C; Vrigneaud JM; Dumont L; Vandroux D; Denat F; Cochet A; Brunotte F; Collin B
    Clin Transl Oncol; 2018 Dec; 20(12):1557-1570. PubMed ID: 29777377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET Imaging of Macrophage Mannose Receptor-Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments.
    Blykers A; Schoonooghe S; Xavier C; D'hoe K; Laoui D; D'Huyvetter M; Vaneycken I; Cleeren F; Bormans G; Heemskerk J; Raes G; De Baetselier P; Lahoutte T; Devoogdt N; Van Ginderachter JA; Caveliers V
    J Nucl Med; 2015 Aug; 56(8):1265-71. PubMed ID: 26069306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
    Park SI; Shenoi J; Pagel JM; Hamlin DK; Wilbur DS; Orgun N; Kenoyer AL; Frayo S; Axtman A; Bäck T; Lin Y; Fisher DR; Gopal AK; Green DJ; Press OW
    Blood; 2010 Nov; 116(20):4231-9. PubMed ID: 20702781
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    D'Huyvetter M; De Vos J; Xavier C; Pruszynski M; Sterckx YGJ; Massa S; Raes G; Caveliers V; Zalutsky MR; Lahoutte T; Devoogdt N
    Clin Cancer Res; 2017 Nov; 23(21):6616-6628. PubMed ID: 28751451
    [No Abstract]   [Full Text] [Related]  

  • 16. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.
    Sharkey RM; Karacay H; Chang CH; McBride WJ; Horak ID; Goldenberg DM
    Leukemia; 2005 Jun; 19(6):1064-9. PubMed ID: 15815716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
    Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
    Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL).
    Weiden PL; Breitz HB
    Crit Rev Oncol Hematol; 2001 Oct; 40(1):37-51. PubMed ID: 11578915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
    Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
    Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.
    Tran L; Baars JW; de Boer JP; Hoefnagel CA; Beijnen JH; Huitema AD
    Hum Antibodies; 2011; 20(1-2):37-40. PubMed ID: 21558622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.